Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Nimotuzumab · OSAG 101

Monoclonal antibody · Antagonist of Epidermal growth factor receptor (EGFR)

Phase 2/3 Most advanced trial (none active)
1 Registered trials

What is Nimotuzumab?

Nimotuzumab is a humanized monoclonal antibody that binds and inhibits the epidermal growth factor receptor (EGFR), resulting in growth inhibition of tumor cells that overexpress EGFR. It is studied in advanced or metastatic pancreatic cancer and may act synergistically with radiation therapy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
OSAG 101
Drug type
Monoclonal antibody
Targets
Epidermal growth factor receptor (EGFR)
Mechanism
Antagonist of Epidermal growth factor receptor (EGFR)
Pathways
EGFR signaling, growth inhibition of EGFR-overexpressing tumor cells
Therapy area
Oncology
In trials of
PRAX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
6NS400BXKH

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00561990 Phase 2/3 Pancreatic Cancer, Advanced or Metastatic Completed PRAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic Cancer, Advanced or Metastatic

Other drugs acting on EGFR

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.